Colorectal cancer treatment outcomes during the pandemic: Our experience of COVID‐19 at a tertiary referral center

Abstract

AbstractBackgroundsThe coronavirus disease 2019 (COVID‐19) has led to major shifts in the management of colorectal cancer (CRC). This study aims to identify the impact and early outcomes of COVID‐19 following CRC management at a tertiary referral center in Victoria, Australia.MethodsThis was a retrospective study, utilizing the Australian Comprehensive Cancer Outcomes and Research Database and inpatient records. Patients presenting for CRC management at our institution were identified coinciding with the first Victorian outbreak of COVID‐19 (March 26 to September 26, 2020) (COVID). Management decisions including chemoradiotherapy utilization and surgical outcomes were analyzed within 6 months and compared with the corresponding period in 2019 (pre‐COVID).ResultsA total of 276 patients were included in this study (147 pre‐COVID period, 129 COVID period). During the COVID period, more patients (47.6% vs. 60.5%; p = 0.033) presented symptomatically and less for surveillance (10.9% vs. 2.3%; p < 0.01). Eighty‐four pre‐COVID and 69 COVID period patients proceeded to surgery. The average time from diagnosis date to surgery was 15.6 days less during the COVID period. There were no significant differences in postoperative utilization of higher care (p = 0.74), complications (p = 0.93), median hospital length of stay (p = 0.67), 30‐day readmission (p = 0.50), or 30‐day reoperation (p = 0.74). In 1.6% of cases, pandemic impacts resulted in a change in management.ConclusionPresentation of patients with CRC varied, with a significant increase in symptomatic presentations and decreased numbers for surveillance. Through flexibility and change in practice, our institution helped improve access to surgical intervention and oncological therapies. Further prospective work is required to identify long‐term outcomes and characterize the effects of ongoing disruptions.